跳至主要内容
临床试验/NCT01061073
NCT01061073已完成3 期

Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial

Poitiers University Hospital1 个研究点 分布在 1 个国家目标入组 73 人开始时间: 2010年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
73
试验地点
1
主要终点
Evaluate the benefit of alpha-blockers (Tamsulosin, group A) compared to phloroglucinol (Spasfon®, group B) as regards patients tolerance to JJ stents

研究概览

简要总结

JJ ureteral stent represents an advance in the management of the upper urinary tract obstruction as it allows the patient to resume his activities although he is stented between the kidney and the bladder.

However, in many cases, this JJ stent is not well tolerated and can even be unbearable.

This trial evaluates the benefit of tamsulosin (an alpha-blocker) in improving the tolerance of JJ stents compared to low-doses of phloroglucinol.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 18 or more.
  • Non-oncological indication to ureteral stenting
  • Informed written consent

排除标准

  • 1 Any contra-indication to Tamsulosin or phloroglucinol (renal or hepatic insufficiency, allergy)
  • Patients already treated with alpha blockers

研究组 & 干预措施

Omexel

Experimental

干预措施: Omexel (Drug)

spasfon

Active Comparator

干预措施: spasfon (Drug)

结局指标

主要结局

Evaluate the benefit of alpha-blockers (Tamsulosin, group A) compared to phloroglucinol (Spasfon®, group B) as regards patients tolerance to JJ stents

时间窗: 1 month treatment

次要结局

  • incidence of complications(after 1 month treatment)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验